Patent · US Active

Determination of apoptotic products in tumor patients undergoing therapy

US7759071B2 · kind B2 · utility

1Cited by

4References

6Claims

0Family size

Assignee

Roche Diagnostics GMBH · DE

Inventors

Stefan HOLDENRIEDER · Munich, DE
Martin Busch · Grafing, DE
Heinz Bodenmueller · Tutzing, DE
Georg Fertig · Penzberg, DE
Andreas Schalhorn · Planegg, DE
Petra Stieber · Gauting, DE

Key dates

Filing date	Apr 23, 2007
Grant date	Jul 20, 2010
Priority date	—
Expiry date	Oct 26, 2028

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The present invention concerns a method for the determination of apoptotic products in samples taken from patients in which apoptosis is induced as a result of disease or therapy, which is characterized in that the concentration of the apoptotic products in samples taken from patients is correlated with the effectiveness of the therapy and thus serves as a follow-up for the therapy. The present invention in particular concerns a method in which the concentration of nucleosomes is determined in serum samples of tumour patients in order to assess the effectiveness of tumour therapy. Furthermore the present invention also concerns the use of a method according to the invention to determine the effectiveness of therapy in tumour patients who are subjected to a radiotherapy or chemotherapy treatment as well as in patients after an acute ischaemic event or after hypothermia treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.